FR2267783A1 - 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis - Google Patents
3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosisInfo
- Publication number
- FR2267783A1 FR2267783A1 FR7414126A FR7414126A FR2267783A1 FR 2267783 A1 FR2267783 A1 FR 2267783A1 FR 7414126 A FR7414126 A FR 7414126A FR 7414126 A FR7414126 A FR 7414126A FR 2267783 A1 FR2267783 A1 FR 2267783A1
- Authority
- FR
- France
- Prior art keywords
- pyridine methanol
- dyslipemia
- atheromatosis
- cerebral
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002490 cerebral effect Effects 0.000 title abstract 2
- IANMPXCZCSTLIG-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid;pyridin-3-ylmethanol Chemical compound OCC1=CC=CN=C1.O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 IANMPXCZCSTLIG-UHFFFAOYSA-N 0.000 title 1
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002093 peripheral effect Effects 0.000 title 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 abstract 4
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 229950003769 acefylline Drugs 0.000 abstract 1
- 230000002744 anti-aggregatory effect Effects 0.000 abstract 1
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- -1 antispasmodics Substances 0.000 abstract 1
- 239000000496 cardiotonic agent Substances 0.000 abstract 1
- 230000003177 cardiotonic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229940125723 sedative agent Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7414126A FR2267783A1 (en) | 1974-04-22 | 1974-04-22 | 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7414126A FR2267783A1 (en) | 1974-04-22 | 1974-04-22 | 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2267783A1 true FR2267783A1 (en) | 1975-11-14 |
| FR2267783B1 FR2267783B1 (index.php) | 1978-07-21 |
Family
ID=9138021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7414126A Granted FR2267783A1 (en) | 1974-04-22 | 1974-04-22 | 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2267783A1 (index.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2639541A1 (fr) * | 1988-11-29 | 1990-06-01 | Fabre Pierre Cosmetique | Amincissants topiques contenant des derives cafeines carboxyliques neutralises par des bases organiques et preparations utiles dans le traitement de la cellulite |
-
1974
- 1974-04-22 FR FR7414126A patent/FR2267783A1/fr active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2639541A1 (fr) * | 1988-11-29 | 1990-06-01 | Fabre Pierre Cosmetique | Amincissants topiques contenant des derives cafeines carboxyliques neutralises par des bases organiques et preparations utiles dans le traitement de la cellulite |
| EP0371874A1 (fr) * | 1988-11-29 | 1990-06-06 | Pierre Fabre Cosmetique | Amincissants topiques contenant des dérives caféines carboxyliques neutralisés par des bases organiques et préparations utiles dans le traitement de la cellulite |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2267783B1 (index.php) | 1978-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tarail | Relation of abnormalities in concentration of serum potassium to electrocardiographic disturbances | |
| IE40858B1 (en) | New benzimidazole derivatives,their preparation,and their use in affecting gastric acid secretion | |
| PT66789A (en) | Process for the preparation of pharmaceutical compositions having high rate of resorption,from heart glicosides,in se hardly resorptive,to be parenterically administered | |
| FR2439194A1 (fr) | Derives de la dibenzothiepine, leur procede de preparation et leur application therapeutique | |
| FR2367750A1 (fr) | Acid | |
| FR2267783A1 (en) | 3-Pyridine methanol theophylline acetate - for treatment of cerebral and peripheral circulatory disorders, dyslipemia and atheromatosis | |
| Liguori et al. | Effects of different dose schedules of amethopterin on serum and tissue concentrations and urinary excretion patterns | |
| US3574831A (en) | Therapeutic heparin-sodium taurocholate compositions | |
| GB1144246A (en) | Improvements in or relating to reduction products of hydroxyisoquinolines | |
| US3108106A (en) | Narcqtine camphosulfonate | |
| Goodman et al. | Inhibition of human tumour clonogenicity by chlorambucil and its metabolites | |
| SU1271520A1 (ru) | Иммуностимул тор | |
| Takagi et al. | The therapeutic effect of FM100, a fraction of licorice root, on acetic acid ulcer in rats | |
| FR2414507A1 (fr) | Trans-eburnamonine et son utilisation pour traiter les insuffisances d'oxygenation tissulaire | |
| Brown-Grant et al. | The secretion of radioactive iodide by the stomach of the anaesthetized dog in relation to total gastric blood flow and to acid secretion | |
| Connolly | Arrhythmias associated with digitalis therapy | |
| FR2260330A1 (en) | Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index | |
| JPS5811856B2 (ja) | ２ ４− ビス （２’ − アセトキシベンズアミド ） アンソクコウサンノ イケイケツシヨウノ セイゾウホウ | |
| SU1437024A1 (ru) | Способ лечени острой почечной недостаточности | |
| SU1646551A1 (ru) | Способ профилактики рецидивов алкоголизма | |
| Robbins et al. | A new mercurial diuretic | |
| SU1584951A1 (ru) | Способ лечени грибовидного микоза | |
| Vinogradov et al. | Digoxin concentration in the blood during the treatment of cardiac insufficiency | |
| FR2434814A1 (fr) | Bromo-2 ergosinine et ses sels d'addition d'acides utiles comme medicaments et un procede de leur preparation | |
| FR2171947A1 (en) | Substd aminomethyl -2,2- diaryl cyclopropanes - for treating anxiety and cardiac insufficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |